Cellular and molecular mechanisms of thoracic aortic aneurysms
Top Cited Papers
- 3 November 2009
- journal article
- review article
- Published by Springer Science and Business Media LLC in Nature Reviews Cardiology
- Vol. 6 (12), 771-786
- https://doi.org/10.1038/nrcardio.2009.191
Abstract
Thoracic aortic aneurysms (TAA) increase the risk of aortic dissection or rupture and represent an important source of morbidity and mortality. Inherited forms of the disease, including Marfan syndrome, have been recognized for a long time but were considered degenerative diseases characterized by cystic medial necrosis of the aortic wall. Improved definition of the structure and function of the normal aortic wall, coupled with the discovery of genetic mutations in key regulatory molecules, have contributed to a more detailed understanding of the pathophysiology of syndromic, familial and sporadic TAAs. We here review the cellular and molecular mechanisms involved in TAA formation and outline areas for future research.Keywords
This publication has 165 references indexed in Scilit:
- Aortopathy Is Prevalent in Relatives of Bicuspid Aortic Valve PatientsJournal of the American College of Cardiology, 2009
- Cyclophilin A enhances vascular oxidative stress and the development of angiotensin II–induced aortic aneurysmsNature Medicine, 2009
- Mutations in Smooth Muscle Alpha-Actin (ACTA2) Cause Coronary Artery Disease, Stroke, and Moyamoya Disease, Along with Thoracic Aortic DiseaseAmerican Journal of Human Genetics, 2009
- Rationale and design of the National Registry of Genetically Triggered Thoracic Aortic Aneurysms and Cardiovascular Conditions (GenTAC)American Heart Journal, 2009
- Characterization of the inflammatory cells in ascending thoracic aortic aneurysms in patients with Marfan syndrome, familial thoracic aortic aneurysms, and sporadic aneurysmsThe Journal of Thoracic and Cardiovascular Surgery, 2008
- Rationale and design of a randomized clinical trial of β-blocker therapy (atenolol) versus angiotensin II receptor blocker therapy (losartan) in individuals with Marfan syndromeAmerican Heart Journal, 2007
- Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular diseaseBiochemical Pharmacology, 2007
- Angiotensin II type 1 receptor blockade attenuates TGF-β–induced failure of muscle regeneration in multiple myopathic statesNature Medicine, 2007
- Spatiotemporal expression and localization of matrix metalloproteinas-9 in a murine model of thoracic aortic aneurysmJournal of Vascular Surgery, 2006
- Mutations in NOTCH1 cause aortic valve diseaseNature, 2005